

MURINE PRECISION-CUT LIVER SLICES AS A DISEASE MODEL TO PREDICT DRUG-INDUCED CHOLESTASIS

Ruby E.H. Karsten, Maciej Grajewski, Gert I.J. Salentijn, Viktoriia Starokozkho, Elisabeth Verpoorte, Peter Olinga
 University of Groningen; Groningen Research Institute of Pharmacy, The Netherlands
 Antonius Deusinglaan 1, P.O. Box 196, 9700 AD Groningen, The Netherlands
 r.e.h.karsten@rug.nl



Introduction Aim

Stages of cholestasis

Figure 1: Four stages of cholestasis development in the liver.

Develop a disease model to study drug-induced cholestasis in precision-cut liver slices (PCLS) in real time.

Materials and Methods

Drug-induced cholestasis

Figure 2: Graphic representation of drug-induced cholestasis with possible disease pathways (1). Drugs and bile acids are actively transported into hepatocytes and subsequently metabolized and secreted into the bile ducts by ATP-dependent transporters. However, in the presence of a cholestatic drug, biliary transport is obstructed and hepatocytes accumulate bile acids in the cell interior. This accumulation is thought to cause hepatocellular apoptosis and necrosis.

Preparation PCLS (2)

(5 mm diameter, 250-300 μm thickness, 5 mg wet weight) at 4°C

Incubation PCLS

In Williams Medium E (37°C, 5% CO₂, 80% O₂)

Analysis

Viability assay

Figure 3: Overview of experimental procedures. Culture medium: Williams Medium E (WME) supplemented with glucose [25 mM] and gentamycin [50 μg/ml] (WME GG). Concentrations chlorpromazine (CPZ): 0, 5, 10, 15 and 20 μM. Concentration bile acid (BA) mix: 30 μM.

Figure 1: Four stages of cholestasis development in the liver. Figure 2: Graphic representation of drug-induced cholestasis with possible disease pathways (1). Figure 3: Overview of experimental procedures. Culture medium: Williams Medium E (WME) supplemented with glucose [25 mM] and gentamycin [50 μg/ml] (WME GG). Concentrations chlorpromazine (CPZ): 0, 5, 10, 15 and 20 μM. Concentration bile acid (BA) mix: 30 μM.

Results




Figure 4: Bar chart of PCLS viability after 48 h incubation, presented with respect to percentage total ATP content of PCLS control slices after 48 h. PCLS were treated with different concentrations of CPZ [0, 5, 10, 15, 20 μM] with and without mouse BA mix [30 μM] (n=7 mice). * indicates p<0.05 and ** indicates p<0.02 significant decrease (two-tailed T-test).

Viability assay shows:

- Concentration-dependent effect of CPZ on PCLS:
 - No toxic effect for 5 and 10 μM CPZ;
 - Low toxicity for 15 μM CPZ;
 - Medium toxicity for 20 μM CPZ
 - Mouse BA mix causes toxicity.
- **Increased toxicity of CPZ + BA mix compared to drug treatment alone.**

Conclusions Outlook

CPZ + BA mix leads to higher toxicity in PCLS than drug treatment alone.

These differences in toxicity are the first results of drug-induced cholestasis in mouse PCLS.

Once optimized:

- Incubate PCLS in continuously perfused microfluidic chip under controlled culture conditions

which will allow drug-induced cholestasis development to be monitored in real time.

References Acknowledgement

(1) Stieger B, Z.M. Mahdi. J Pharm Sci. 106: 2295-2301, 2017
 (2) de Graaf IAM, et al. Nat Protoc. 5(9):1540-51, 2010

TisuMR project is funded by European Commission
 Project number: 190634130

